The current possible treatment approaches of Polycystic Ovary Syndrome (PCOS)
DOI:
https://doi.org/10.12775/JEHS.2024.59.011Keywords
PCOS, PCOS treatment, PCOS medicationsAbstract
Introduction
Polycystic ovary syndrome (PCOS), first described by Stein and Leventhal in 1935, is one of the most prevalent endocrine system conditions affecting women of reproductive age. It affects between 6% and 13% of women and the majority of cases are identified between the ages of 20 and 30. Unfortunately, the disease is usually diagnosed only when bothersome symptoms such as hair loss, alopecia, acne, and infertility-related problems occur. Based on the Rotterdam criteria, four phenotypes of PCOS are distinguished.
Aim of the study
This review aims to present the current state of knowledge about possible treatment approaches, both non-pharmacological and pharmacological.
Materials and methods
The paper was created based on the Pubmed database. The literature was reviewed using the keywords: ”PCOS”, ”PCOS treatment” and “ PCOS medications “.
The current state of knowledge
Treatments for PCOS must be tailored to the specific needs of each patient. In the management of PCOS, special attention is paid to diet, physical activity, and restoration of the Gut Microbiome. Medications used in therapy are oral contraceptives and anti-androgens, insulin sensitizers, ovulation inducers, calcium and vitamin D supplements, statins, Glucagon-like-peptide-1 (GLP-1) agonists, inositols and interleukin 22 (IL-22) therapy.
Summary
Treatment options for menstrual irregularities and hirsutism are based on the clinical goals and preferences of the patient. The ideal would be causal treatment, but due to the ongoing lack of full understanding of the pathogenesis of the syndrome, is not entirely feasible. The ideal would be causal treatment, but due to the ongoing lack of full understanding of the pathogenesis of the syndrome, is not entirely feasible. The most important is a multimodal approach to treat comorbid conditions such as diabetes mellitus type 2, obesity, hyperlipidemia, depression, and infertility.
References
El Hayek S, Bitar L, Hamdar LH, Mirza FG, Daoud G. Poly Cystic Ovarian Syndrome: An Updated Overview. Front Physiol. 2016 Apr 5;7:124. doi: 10.3389/fphys.2016.00124. PMID: 27092084; PMCID: PMC4820451.
Stein I. F., Leventhal M. L. (1935). Amenorrhea associated with bilateral polycystic ovaries. Am. J. Obstet. Gynecol. 29, 181–191. 10.1016/S0002-9378(15)30642-6
Neven ACH, Laven J, Teede HJ, Boyle JA. A Summary on Polycystic Ovary Syndrome: Diagnostic Criteria, Prevalence, Clinical Manifestations, and Management According to the Latest International Guidelines. Semin Reprod Med. 2018 Jan;36(1):5-12. doi: 10.1055/s-0038-1668085. Epub 2018 Sep 6. PMID: 30189445.
Vidya Bharathi R., Swetha S., Neerajaa J., Varsha Madhavica J., Janani D.M., Rekha S.N., Ramya S., Usha B. An epidemiological survey: Effect of predisposing factors for PCOS in Indian urban and rural population. Middle East Fertil. Soc. J. 2017;22:313–316. doi: 10.1016/j.mefs.2017.05.007.
Shrivastava S, Conigliaro RL. Polycystic Ovarian Syndrome. Med Clin North Am. 2023 Mar;107(2):227-234. doi: 10.1016/j.mcna.2022.10.004. Epub 2022 Dec 26. PMID: 36759093.
Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004 Jun;89(6):2745-9. doi: 10.1210/jc.2003-032046. PMID: 15181052.
Bremer AA. Polycystic ovary syndrome in the pediatric population. Metab Syndr Relat Disord. 2010 Oct;8(5):375-94. doi: 10.1089/met.2010.0039. PMID: 20939704; PMCID: PMC3125559.
Lujan ME, Chizen DR, Pierson RA. Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies. J Obstet Gynaecol Can. 2008 Aug;30(8):671-679. doi: 10.1016/S1701-2163(16)32915-2. PMID: 18786289; PMCID: PMC2893212.
Ibáñez L, Oberfield SE, Witchel S, Auchus RJ, Chang RJ, Codner E, Dabadghao P, Darendeliler F, Elbarbary NS, Gambineri A, Garcia Rudaz C, Hoeger KM, López-Bermejo A, Ong K, Peña AS, Reinehr T, Santoro N, Tena-Sempere M, Tao R, Yildiz BO, Alkhayyat H, Deeb A, Joel D, Horikawa R, de Zegher F, Lee PA. An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence. Horm Res Paediatr. 2017;88(6):371-395. doi: 10.1159/000479371. Epub 2017 Nov 13. PMID: 29156452.
Barrea L, Marzullo P, Muscogiuri G, Di Somma C, Scacchi M, Orio F, Aimaretti G, Colao A, Savastano S. Source and amount of carbohydrate in the diet and inflammation in women with polycystic ovary syndrome. Nutr Res Rev. 2018 Dec;31(2):291-301. doi: 10.1017/S0954422418000136. Epub 2018 Jul 23. PMID: 30033891.
Shahid R, Iahtisham-Ul-Haq, Mahnoor, Awan KA, Iqbal MJ, Munir H, Saeed I. Diet and lifestyle modifications for effective management of polycystic ovarian syndrome (PCOS). J Food Biochem. 2022 Jul;46(7):e14117. doi: 10.1111/jfbc.14117. Epub 2022 Feb 24. PMID: 35199348.
Giampaolino P, Foreste V, Di Filippo C, Gallo A, Mercorio A, Serafino P, Improda FP, Verrazzo P, Zara G, Buonfantino C, Borgo M, Riemma G, Angelis C, Zizolfi B, Bifulco G, Della Corte L. Microbiome and PCOS: State-of-Art and Future Aspects. Int J Mol Sci. 2021 Feb 19;22(4):2048. doi: 10.3390/ijms22042048. PMID: 33669557; PMCID: PMC7922491.
Ahmadi S, Jamilian M, Karamali M, Tajabadi-Ebrahimi M, Jafari P, Taghizadeh M, Memarzadeh MR, Asemi Z. Probiotic supplementation and the effects on weight loss, glycaemia and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Hum Fertil (Camb). 2017 Dec;20(4):254-261. doi: 10.1080/14647273.2017.1283446. Epub 2017 Feb 1. Update in: Hum Fertil (Camb). 2021 Dec;24(5):395. PMID: 28142296.
Shoaei T, Heidari-Beni M, Tehrani HG, Feizi A, Esmaillzadeh A, Askari G. Effects of Probiotic Supplementation on Pancreatic β-cell Function and C-reactive Protein in Women with Polycystic Ovary Syndrome: A Randomized Double-blind Placebo-controlled Clinical Trial. Int J Prev Med. 2015 Mar 24;6:27. doi: 10.4103/2008-7802.153866. PMID: 25949777; PMCID: PMC4387688.
Heshmati J, Farsi F, Yosaee S, Razavi M, Rezaeinejad M, Karimie E, Sepidarkish M. The Effects of Probiotics or Synbiotics Supplementation in Women with Polycystic Ovarian Syndrome: a Systematic Review and Meta-Analysis of Randomized Clinical Trials. Probiotics Antimicrob Proteins. 2019 Dec;11(4):1236-1247. doi: 10.1007/s12602-018-9493-9. PMID: 30547393.
Shamasbi SG, Ghanbari-Homayi S, Mirghafourvand M. The effect of probiotics, prebiotics, and synbiotics on hormonal and inflammatory indices in women with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Nutr. 2020 Mar;59(2):433-450. doi: 10.1007/s00394-019-02033-1. Epub 2019 Jun 29. PMID: 31256251.
Calcaterra V, Rossi V, Massini G, Casini F, Zuccotti G, Fabiano V. Probiotics and Polycystic Ovary Syndrome: A Perspective for Management in Adolescents with Obesity. Nutrients. 2023 Jul 14;15(14):3144. doi: 10.3390/nu15143144. PMID: 37513562; PMCID: PMC10384396.
Tabrizi R, Ostadmohammadi V, Akbari M, Lankarani KB, Vakili S, Peymani P, Karamali M, Kolahdooz F, Asemi Z. The Effects of Probiotic Supplementation on Clinical Symptom, Weight Loss, Glycemic Control, Lipid and Hormonal Profiles, Biomarkers of Inflammation, and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis of Randomized Controlled Trials. Probiotics Antimicrob Proteins. 2022 Feb;14(1):1-14. doi: 10.1007/s12602-019-09559-0. PMID: 31165401.
Fernandes R, do Rosario VA, Mocellin MC, Kuntz MGF, Trindade EBSM. Effects of inulin-type fructans, galacto-oligosaccharides and related synbiotics on inflammatory markers in adult patients with overweight or obesity: A systematic review. Clin Nutr. 2017 Oct;36(5):1197-1206. doi: 10.1016/j.clnu.2016.10.003. Epub 2016 Oct 8. PMID: 27771020.
Gholizadeh Shamasbi S, Dehgan P, Mohammad-Alizadeh Charandabi S, Aliasgarzadeh A, Mirghafourvand M. The effect of resistant dextrin as a prebiotic on metabolic parameters and androgen level in women with polycystic ovarian syndrome: a randomized, triple-blind, controlled, clinical trial. Eur J Nutr. 2019 Mar;58(2):629-640. doi: 10.1007/s00394-018-1648-7. Epub 2018 Feb 26. PMID: 29480399.
Quaranta G, Sanguinetti M, Masucci L. Fecal Microbiota Transplantation: A Potential Tool for Treatment of Human Female Reproductive Tract Diseases. Front Immunol. 2019 Nov 26;10:2653. doi: 10.3389/fimmu.2019.02653. PMID: 31827467; PMCID: PMC6890827.
Alesi S, Forslund M, Melin J, Romualdi D, Peña A, Tay CT, Witchel SF, Teede H, Mousa A. Efficacy and safety of anti-androgens in the management of polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine. 2023 Aug 9;63:102162. doi: 10.1016/j.eclinm.2023.102162. PMID: 37583655; PMCID: PMC10424142.
Lizneva D, Gavrilova-Jordan L, Walker W, Azziz R. Androgen excess: Investigations and management. Best Pract Res Clin Obstet Gynaecol. 2016 Nov;37:98-118. doi: 10.1016/j.bpobgyn.2016.05.003. Epub 2016 May 19. PMID: 27387253.
Forslund M, Melin J, Alesi S, Piltonen T, Romualdi D, Tay CT, Witchel S, Pena A, Mousa A, Teede H. Different kinds of oral contraceptive pills in polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Endocrinol. 2023 Jul 20;189(1):S1-S16. doi: 10.1093/ejendo/lvad082. PMID: 37440702.
Tang Z, Guan J, Mao JH, Han L, Zhang JJ, Chen R, Jiao Z. Quantitative risk-benefit profiles of oral contraceptives, insulin sensitizers and antiandrogens for women with polycystic ovary syndrome: A model-based meta-analysis. Eur J Pharm Sci. 2023 Nov 1;190:106577. doi: 10.1016/j.ejps.2023.106577. Epub 2023 Sep 2. PMID: 37666459.
Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 Dec;98(12):4565-92. doi: 10.1210/jc.2013-2350. Epub 2013 Oct 22. Erratum in: J Clin Endocrinol Metab. 2021 May 13;106(6):e2462. PMID: 24151290; PMCID: PMC5399492.
Armanini D, Boscaro M, Bordin L, Sabbadin C. Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism. Int J Mol Sci. 2022 Apr 8;23(8):4110. doi: 10.3390/ijms23084110. PMID: 35456928; PMCID: PMC9030414.
Bharath LP, Nikolajczyk BS. The intersection of metformin and inflammation. Am J Physiol Cell Physiol. 2021 May 1;320(5):C873-C879. doi: 10.1152/ajpcell.00604.2020. Epub 2021 Mar 10. PMID: 33689478; PMCID: PMC8163577.
Elsenbruch S, Hahn S, Kowalsky D, Offner AH, Schedlowski M, Mann K, Janssen OE. Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003 Dec;88(12):5801-7. doi: 10.1210/jc.2003-030562. PMID: 14671172.
Attia GM, Almouteri MM, Alnakhli FT. Role of Metformin in Polycystic Ovary Syndrome (PCOS)-Related Infertility. Cureus. 2023 Aug 31;15(8):e44493. doi: 10.7759/cureus.44493. PMID: 37791160; PMCID: PMC10544455.
Al-Thuwaynee S, Swadi AAJ. Comparing efficacy and safety of stair step protocols for clomiphene citrate and letrozole in ovulation induction for women with polycystic ovary syndrome (PCOS): a randomized controlled clinical trial. J Med Life. 2023 May;16(5):725-730. doi: 10.25122/jml-2023-0069. PMID: 37520487; PMCID: PMC10375350.
Liu Z, Geng Y, Huang Y, Hu R, Li F, Song Y, Zhang M. Letrozole Compared With Clomiphene Citrate for Polycystic Ovarian Syndrome: A Systematic Review and Meta-analysis. Obstet Gynecol. 2023 Mar 1;141(3):523-534. doi: 10.1097/AOG.0000000000005070. Epub 2023 Feb 2. PMID: 36735392.
Lin MW, Wu MH. The role of vitamin D in polycystic ovary syndrome. Indian J Med Res. 2015 Sep;142(3):238-40. doi: 10.4103/0971-5916.166527. PMID: 26458338; PMCID: PMC4669857.
Shojaeian Z, Sadeghi R, Latifnejad Roudsari R. Calcium and vitamin D supplementation effects on metabolic factors, menstrual cycles and follicular responses in women with polycystic ocvary syndrome: A systematic review and meta-analysis. Caspian J Intern Med. 2019 Fall;10(4):359-369. doi: 10.22088/cjim.10.4.359. PMID: 31814932; PMCID: PMC6856914.
Kodaman PH, Duleba AJ. HMG-CoA reductase inhibitors: do they have potential in the treatment of polycystic ovary syndrome? Drugs. 2008;68(13):1771-85. doi: 10.2165/00003495-200868130-00001. PMID: 18729532.
Izquierdo D, Foyouzi N, Kwintkiewicz J, Duleba AJ. Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis. Fertil Steril. 2004 Oct;82 Suppl 3:1193-7. doi: 10.1016/j.fertnstert.2004.03.037. PMID: 15474095.
Sathyapalan T, Smith KA, Coady AM, Kilpatrick ES, Atkin SL. Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Ann Clin Biochem. 2012 Jan;49(Pt 1):80-5. doi: 10.1258/acb.2011.011071. Epub 2011 Oct 4. PMID: 21972424.
Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2010 Apr;72(4):566-8. doi: 10.1111/j.1365-2265.2009.03678.x. Epub 2009 Aug 4. PMID: 19681918.
Miao K, Zhou H. Effect of statins combined or not combined with metformin on polycystic ovary syndrome: A systematic review and meta-analysis. J Obstet Gynaecol Res. 2022 Jul;48(7):1806-1815. doi: 10.1111/jog.15301. Epub 2022 May 27. PMID: 35620917.
Siamashvili M, Davis SN. Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. Expert Rev Clin Pharmacol. 2021 Sep;14(9):1081-1089. doi: 10.1080/17512433.2021.1933433. Epub 2021 May 27. PMID: 34015974.
Jensterle M, Goricar K, Janez A. Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study. Exp Ther Med. 2016 Apr;11(4):1194-1200. doi: 10.3892/etm.2016.3081. Epub 2016 Feb 16. PMID: 27073422; PMCID: PMC4812364.
Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008 Jul;93(7):2670-8. doi: 10.1210/jc.2008-0115. Epub 2008 May 6. PMID: 18460557.
Szczesnowicz A, Szeliga A, Niwczyk O, Bala G, Meczekalski B. Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies. J Clin Med. 2023 Sep 12;12(18):5915. doi: 10.3390/jcm12185915. PMID: 37762856; PMCID: PMC10532286.
Zhao H, Xing C, Zhang J, He B. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. Reprod Health. 2021 Aug 18;18(1):171. doi: 10.1186/s12978-021-01207-7. PMID: 34407851; PMCID: PMC8371888.
Bevilacqua A, Bizzarri M. Inositols in Insulin Signaling and Glucose Metabolism. Int J Endocrinol. 2018 Nov 25;2018:1968450. doi: 10.1155/2018/1968450. PMID: 30595691; PMCID: PMC6286734.
Ravanos K, Monastra G, Pavlidou T, Goudakou M, Prapas N. Can high levels of D-chiro-inositol in follicular fluid exert detrimental effects on blastocyst quality? Eur Rev Med Pharmacol Sci. 2017 Dec;21(23):5491-5498. doi: 10.26355/eurrev_201712_13940. PMID: 29243796.
Gateva A, Unfer V, Kamenov Z. The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review. Gynecol Endocrinol. 2018 Jul;34(7):545-550. doi: 10.1080/09513590.2017.1421632. Epub 2018 Jan 8. PMID: 29309199.
Fruzzetti F, Perini D, Russo M, Bucci F, Gadducci A. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol. 2017 Jan;33(1):39-42. doi: 10.1080/09513590.2016.1236078. Epub 2016 Nov 3. PMID: 27808588.
Xing C, Li C, He B. Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS. J Clin Endocrinol Metab. 2020 Sep 1;105(9):2950–63. doi: 10.1210/clinem/dgaa337. PMID: 32490533; PMCID: PMC7365687.
Donà G, Sabbadin C, Fiore C, Bragadin M, Giorgino FL, Ragazzi E, Clari G, Bordin L, Armanini D. Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. Eur J Endocrinol. 2012 Apr;166(4):703-10. doi: 10.1530/EJE-11-0840. Epub 2012 Jan 5. PMID: 22223702.
Dinicola S, Unfer V, Facchinetti F, Soulage CO, Greene ND, Bizzarri M, Laganà AS, Chan SY, Bevilacqua A, Pkhaladze L, Benvenga S, Stringaro A, Barbaro D, Appetecchia M, Aragona C, Bezerra Espinola MS, Cantelmi T, Cavalli P, Chiu TT, Copp AJ, D'Anna R, Dewailly D, Di Lorenzo C, Diamanti-Kandarakis E, Hernández Marín I, Hod M, Kamenov Z, Kandaraki E, Monastra G, Montanino Oliva M, Nestler JE, Nordio M, Ozay AC, Papalou O, Porcaro G, Prapas N, Roseff S, Vazquez-Levin M, Vucenik I, Wdowiak A. Inositols: From Established Knowledge to Novel Approaches. Int J Mol Sci. 2021 Sep 30;22(19):10575. doi: 10.3390/ijms221910575. PMID: 34638926; PMCID: PMC8508595.
Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F, Kumar M. Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics. J Clin Med. 2023 Feb 11;12(4):1454. doi: 10.3390/jcm12041454. PMID: 36835989; PMCID: PMC9964744.
De Leo V, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev. 2003 Oct;24(5):633-67. doi: 10.1210/er.2002-0015. PMID: 14570747.
Qi X, Yun C, Sun L, Xia J, Wu Q, Wang Y, Wang L, Zhang Y, Liang X, Wang L, Gonzalez FJ, Patterson AD, Liu H, Mu L, Zhou Z, Zhao Y, Li R, Liu P, Zhong C, Pang Y, Jiang C, Qiao J. Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome. Nat Med. 2019 Aug;25(8):1225-1233. doi: 10.1038/s41591-019-0509-0. Epub 2019 Jul 22. Erratum in: Nat Med. 2019 Sep;25(9):1459. PMID: 31332392; PMCID: PMC7376369.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Justyna Lipińska, Maria Kowalczuk, Łukasz Lipiński, Izabela Kopeć, Jakub Kamiński, Klaudia Klimczak, Laura Loryś, Marcin Narloch, Stanisław Kasprzak, Karolina Kasprzak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 430
Number of citations: 0